Von Willebrand Disease Tests: Diagnosing Hereditary Bleeding Disorders

Introduction: What is Von Willebrand Disease (VWD)?

Von Willebrand Disease (VWD) is one of the most common hereditary bleeding disorders worldwide. It is caused by a deficiency or dysfunction of a specific blood protein known as "Von Willebrand Factor" (VWF). This protein plays a critical role in blood clotting by helping platelets adhere to each other and to the damaged blood vessel walls. Without sufficient or functional VWF, individuals experience difficulty stopping bleeding after injuries, surgeries, or even spontaneously in severe cases.

Because symptoms can range from very mild to severe, diagnosing VWD requires a precise, multi-stage laboratory approach. This article aims to shed light on Von Willebrand Disease tests and how they are used to achieve an accurate diagnosis to manage the condition effectively and safely.

Symptoms Demanding VWD Testing

VWD is usually suspected when a patient or doctor notices an abnormal bleeding pattern. The most common symptoms that prompt laboratory evaluation include:

• Easy and frequent bruising without an obvious cause or after minor trauma.
• Recurrent, hard-to-stop nosebleeds (epistaxis) lasting longer than 10 minutes.
• Excessive or prolonged bleeding after dental procedures or minor surgeries.
• Heavy menstrual bleeding in women (menorrhagia), requiring very frequent pad changes or lasting more than seven days.
• An unexplained family history of bleeding disorders or easy bruising.

The Diagnostic Journey: Why is VWD Diagnosis Complex?

Diagnosing VWD does not rely on a single, simple test. VWF levels in the body fluctuate naturally in response to various factors such as stress, physical exertion, pregnancy, infections, and hormones. Therefore, physicians may need to repeat tests several times over intervals to confirm the diagnosis and rule out false positives or negatives. Additionally, diagnosis requires distinguishing between the three main types of VWD (Type 1, Type 2, and Type 3) to ensure an appropriate treatment plan.

Primary Screening Tests for Coagulation and Bleeding

Before moving to specific VWF tests, doctors typically order a set of general screening tests to evaluate overall clotting and platelet function. These include:

• Complete Blood Count (CBC): Used to check platelet count and size, and to rule out anemia caused by ongoing bleeding.
• Prothrombin Time (PT): Measures the efficiency of the extrinsic and common coagulation pathways, which is usually normal in VWD patients.
• Activated Partial Thromboplastin Time (aPTT): Measures the intrinsic pathway. This test may show prolongation in some VWD patients due to VWF's role in carrying and protecting Factor VIII from degradation.

The Specialized VWD Diagnostic Panel

If screening tests or clinical history suggest VWD, a specialized panel of tests is ordered to directly measure VWF quantity and function. This panel typically consists of three main tests performed together:

1. VWF Antigen Test (VWF:Ag)

This test measures the total amount of Von Willebrand Factor protein present in the blood plasma, regardless of its functional capability. It helps detect quantitative deficiencies.

2. VWF Activity Test (VWF:Act / Ristocetin Cofactor)

This test measures how well the VWF protein functions and binds to platelets. The compound "ristocetin" is used in the lab to stimulate this binding. A low activity level relative to the total antigen level suggests a qualitative defect (Type 2).

3. Factor VIII Activity Test (FVIII:C)

Since VWF acts as a carrier protein that stabilizes Factor VIII (an important clotting protein), a deficiency in VWF often leads to a secondary decrease in Factor VIII levels. Measuring its activity helps assess severity and guide treatment.

Confirmatory and Advanced Tests to Determine VWD Type

In cases where initial panel results are inconclusive, or to determine the exact subtype of VWD, a hematologist may request advanced testing:

• VWF Multimer Analysis: This test examines the structural composition of the VWF protein to see if large, active molecules are missing, which is crucial for diagnosing Type 2 subtypes.
• Genetic Testing: Used in specific cases to identify gene mutations responsible for VWD, aiding in family genetic counseling and confirming complex cases.

How to Prepare for VWD Testing

To ensure accurate results and avoid factors that temporarily elevate VWF levels (potentially masking the disease), patients should follow these guidelines:

• Avoid strenuous physical exercise for at least 24 hours before the test.
• Inform the doctor of all medications and supplements, especially oral contraceptives or hormone therapies, which can raise VWF levels.
• Perform the test during a period of physical and emotional stability, as acute stress or infections can temporarily elevate VWF levels.
• For women, the doctor may prefer to schedule the test during specific phases of the menstrual cycle to minimize hormonal influence.

Interpreting Test Results and Understanding VWD Types

The following table illustrates how physicians interpret VWD panel results to classify the disease type:

Factors Affecting Test Accuracy

The clinical team must consider several physiological and pathological factors that can affect VWF levels and lead to misdiagnosis:

• Blood Type: Individuals with blood type O naturally have VWF levels that are 20% to 30% lower than those with other blood types (A, B, AB), which must be factored into interpretation.
• Pregnancy: VWF levels rise significantly during pregnancy, which can temporarily mask mild VWD in pregnant women.
• Acute Phase Response: VWF is an acute-phase reactant that increases during active inflammation, infection, or recent surgery.

Clinical Guidance and Next Steps After Diagnosis

Once a diagnosis is confirmed and the VWD type is identified, the patient should maintain regular follow-ups with a hematology consultation to establish a personalized care plan. General recommendations include:

• Avoiding medications that increase bleeding risk or affect platelet function, such as aspirin and NSAIDs (e.g., ibuprofen), unless prescribed by a doctor.
• Informing all healthcare providers, including dentists and surgeons, about the diagnosis before any medical or surgical procedure.
• Discussing available treatment options to control bleeding, such as desmopressin (DDAVP) for mild types, or clotting factor concentrates containing VWF for more severe cases.